ISCO and Insight Bioventures India structure Indian affiliate to develop stem cell-based eye products for Asia

International Stem Cell Corp (OTCBB: ISCO.ob) and Insight Bioventures India Private (IBVI) have agreed on financial and structural terms for establishing an Indian affiliate of ISCO (ISCO India). This is an important milestone in ISCO and IBVI’s goal to facilitate development and commercialization of ISCO’s stem-cell derived corneal tissue, CytoCor, and retinal cells, CytoRet, for the treatment of blindness and severe vision impairment as well as cell systems for drug screening in India and establish a manufacturing base for ISCO’s Lifeline Cell Technology (Lifeline) brand of cell culture media for commercialization throughout Asia.

The agreed financial and structural terms will enable the formation of ISCO India as a majority-owned Indian affiliate of ISCO, initially with laboratories in India’s first clinical research facility for stem cells and regenerative medicine in Hyderabad with the intent to relocate to India’s first platinum-rated research center, MARG Science Park, in Chennai. The park is a member of International Association of Sciences Parks (IASP) and has established networking and alliances with renowned institutes and organizations.

Will supply Lifeline’s Asian distributors